Telomir Pharmaceuticals (TELO) Competitors $1.13 -0.04 (-3.42%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.16 +0.03 (+2.21%) As of 07/15/2025 07:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock TELO vs. GALT, SKYE, LYEL, RAPT, GLSI, ALTS, CRBU, FTLF, UPXI, and FATEShould you be buying Telomir Pharmaceuticals stock or one of its competitors? The main competitors of Telomir Pharmaceuticals include Galectin Therapeutics (GALT), Skye Bioscience (SKYE), Lyell Immunopharma (LYEL), Rapt Therapeutics (RAPT), Greenwich LifeSciences (GLSI), ALT5 Sigma (ALTS), Caribou Biosciences (CRBU), FitLife Brands (FTLF), Upexi (UPXI), and Fate Therapeutics (FATE). These companies are all part of the "pharmaceutical products" industry. Telomir Pharmaceuticals vs. Its Competitors Galectin Therapeutics Skye Bioscience Lyell Immunopharma Rapt Therapeutics Greenwich LifeSciences ALT5 Sigma Caribou Biosciences FitLife Brands Upexi Fate Therapeutics Telomir Pharmaceuticals (NASDAQ:TELO) and Galectin Therapeutics (NASDAQ:GALT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation. Which has better earnings & valuation, TELO or GALT? Galectin Therapeutics is trading at a lower price-to-earnings ratio than Telomir Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTelomir PharmaceuticalsN/AN/A-$16.53M-$0.42-2.69Galectin TherapeuticsN/AN/A-$47.05M-$0.72-3.89 Does the media refer more to TELO or GALT? In the previous week, Galectin Therapeutics had 2 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 3 mentions for Galectin Therapeutics and 1 mentions for Telomir Pharmaceuticals. Telomir Pharmaceuticals' average media sentiment score of 1.89 beat Galectin Therapeutics' score of 0.85 indicating that Telomir Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Telomir Pharmaceuticals Very Positive Galectin Therapeutics Positive Do analysts prefer TELO or GALT? Telomir Pharmaceuticals currently has a consensus price target of $15.00, indicating a potential upside of 1,227.43%. Galectin Therapeutics has a consensus price target of $6.00, indicating a potential upside of 114.29%. Given Telomir Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Telomir Pharmaceuticals is more favorable than Galectin Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Telomir Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 1 Strong Buy rating(s) 3.50Galectin Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility & risk, TELO or GALT? Telomir Pharmaceuticals has a beta of -0.9, indicating that its share price is 190% less volatile than the S&P 500. Comparatively, Galectin Therapeutics has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Do institutionals and insiders have more ownership in TELO or GALT? 11.7% of Galectin Therapeutics shares are held by institutional investors. 50.1% of Galectin Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Is TELO or GALT more profitable? Galectin Therapeutics' return on equity of 0.00% beat Telomir Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Telomir PharmaceuticalsN/A -2,009.40% -1,009.72% Galectin Therapeutics N/A N/A -216.05% SummaryTelomir Pharmaceuticals beats Galectin Therapeutics on 7 of the 13 factors compared between the two stocks. Get Telomir Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for TELO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TELO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TELO vs. The Competition Export to ExcelMetricTelomir PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$34.82M$2.44B$5.62B$9.30BDividend YieldN/A1.79%4.25%4.03%P/E Ratio-2.699.1428.5719.58Price / SalesN/A676.39423.3593.84Price / CashN/A164.3436.0257.93Price / Book56.504.608.135.54Net Income-$16.53M$30.99M$3.24B$257.73M7 Day Performance-3.83%-1.81%0.16%-0.08%1 Month Performance-43.50%5.73%5.95%8.09%1 Year Performance-72.84%-7.03%26.09%13.02% Telomir Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TELOTelomir Pharmaceuticals3.5383 of 5 stars$1.13-3.4%$15.00+1,227.4%-72.7%$34.82MN/A-2.691Positive NewsHigh Trading VolumeGALTGalectin Therapeutics2.2542 of 5 stars$2.09-2.8%$6.00+187.1%+17.6%$136.08MN/A-2.909Positive NewsSKYESkye Bioscience2.1464 of 5 stars$4.35-0.9%$16.60+281.6%-40.6%$135.98MN/A-5.3011LYELLyell Immunopharma3.4652 of 5 stars$9.34+2.1%$15.00+60.6%-73.5%$135.49M$60K0.00270News CoverageRAPTRapt Therapeutics4.3805 of 5 stars$8.03-1.6%$24.00+198.9%-62.9%$134.93M$1.53M-0.4280News CoverageAnalyst RevisionGap UpTrading HaltedGLSIGreenwich LifeSciences2.154 of 5 stars$10.09+0.2%$39.00+286.5%-35.6%$134.62MN/A-8.013ALTSALT5 Sigma0.1329 of 5 stars$7.19-4.6%N/AN/A$131.61M$12.53M0.00170CRBUCaribou Biosciences2.9182 of 5 stars$1.60+15.1%$8.50+431.3%-24.4%$129.28M$9.99M0.00100FTLFFitLife Brands4.0374 of 5 stars$13.50-1.8%$20.50+51.9%-19.3%$129.13M$64.47M15.9020High Trading VolumeUPXIUpexi2.6021 of 5 stars$4.13+26.7%$16.00+287.4%-39.5%$123.60M$26M0.00130High Trading VolumeFATEFate Therapeutics3.5165 of 5 stars$1.09+2.8%$3.83+251.7%-71.0%$121.48M$13.63M-0.73550 Related Companies and Tools Related Companies Galectin Therapeutics Alternatives Skye Bioscience Alternatives Lyell Immunopharma Alternatives Rapt Therapeutics Alternatives Greenwich LifeSciences Alternatives ALT5 Sigma Alternatives Caribou Biosciences Alternatives FitLife Brands Alternatives Upexi Alternatives Fate Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TELO) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredThis Social Security Shift Could Boost Benefits by 400%If you currently collect Social Security—or plan to in the future—this may be one of the most important update...InvestorPlace | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Telomir Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Telomir Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free TELO Stock Alerts